このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

髄芽腫に対する頭蓋脊髄放射線照射を受けた小児の脳修復のためのメトホルミン

2026年9月21日 更新者:Donald Mabbott、The Hospital for Sick Children

髄芽腫に対する頭蓋脊髄放射線照射を受けた小児の脳修復を目的としたメトホルミンのプラセボ対照二重盲検クロスオーバー試験

A placebo controlled double blind crossover trial of metformin in 30 children treated with radiation for medulloblastoma - the most common malignant brain tumour. The investigators used tests of thinking and learning and brain imaging techniques to examine whether metformin can enhance cognition or promote brain repair following radiation-induced brain injury.

調査の概要

詳細な説明

We conducted a pilot randomized, double-blind, placebo-controlled trial with crossover in survivors of pediatric brain tumors with primary endpoints of safety and feasibility and secondary endpoints of cognitive and magnetic resonance imaging (MRI) measures. Twenty-four participants were enrolled and randomly assigned to complete 12-week cycles of metformin (A) and placebo (B) in either a group AB (AB) or group BA (BA) sequence. At the point of crossover, there was a 10-week washout period in which neither group received any treatment. During the first week of each treatment cycle, a daily dose of 500 mg/m2 of metformin or placebo was administered orally. The dose was increased to 1000mg/m2 daily beginning in the second week and continuing for the remainder of the 12-week cycle.

Test procedures (Clinical & current medications reviews, Blood draws, and MRI and Cognitive testing) were performed at 4 times points during the study: 1. at study entry (Baseline 1), 2. after 12 weeks of treatment (Outcome 1), 3. after a 10-week washout period at 22 weeks (Baseline 2), and 4. At the end of the trial at 34 weeks (Outcome 2).

研究の種類

介入

入学 (実際)

24

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Ontario
      • Toronto、Ontario、カナダ、M5G 1X8
        • The Hospital for Sick Children

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

5年~21年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion criteria: Survivors will be included if they:

  1. Have been treated with cranial or cranial-spinal radiation,

  2. Are between 5 and 21 years of age at time of consent, and

  3. Either declare English as their native language or have had at least two years of schooling in English at the time of their baseline assessment.

  4. Have been diagnosed with a brain tumour requiring treatment with cranial or cranial-spinal radiation at least 2 years ago, is not receiving active treatment and no more than 15 years may have elapsed between treatment with cranial-spinal radiation and time of the trial. Survivors with a shunt will be included in the trial, but will need to be identified prior to study enrollment to discuss any specific considerations for imaging.

  5. Meet criteria for adequate organ function requirements:

    1. Adequate renal function defined as: Creatinine clearance or radioisotope glomerular filtration rate (GFR) > 70ml/min/1.73 m2 or serum creatinine based on age/gender as follows:

      Maximum Serum Creatinine Level (mg/dL)

      5 to < 10 years: Male = 1; Female = 1

      10 to < 13 years: Male = 1.2; Female = 1.2

      13 to < 16 years: Male = 1.5; Female = 1.4

      ≥ 16 years: Male = 1.7; Female = 1.4

    2. Adequate liver function defined as:

    Total bilirubin < 1.5 x upper limit of normal (ULN) for age, and,

    serum glutamate oxaloacetate transaminase (SGOT) (AST) or serum glutamate pyruvate transaminase (SGPT) (ALT) < 3 x upper limit of normal (ULN) for age.

  6. Females of childbearing potential must have a negative pregnancy test result and must agree to use a medically acceptable method of contraception throughout the entire study period and for 30 days after the last dose of study drug.

  7. Informed consent will be obtained from the participants and/or their legal guardians by study team members authorized to consent for this study.

Exclusion criteria: Survivors will be excluded if they

  1. Are receiving palliative care.
  2. Are unable to participate in neuro-imaging without sedation as this is the primary outcome measure for the trial.
  3. Are unable to swallow tablets.
  4. Are unstable and/or insulin-dependent (Type 1) diabetic patients.
  5. Have acute or chronic metabolic acidosis and/or lactic acidosis.
  6. Any female patient or partner who has reached menarche and male patients who are not willing to use an effective method of contraception.
  7. Patient who is pregnant or lactating and does not agree to stop breastfeeding while receiving trial treatment.
  8. Have a history of renal disease or renal dysfunction e.g., as suggested by elevated serum creatinine levels (see 5.a. Inclusion criteria) or abnormal creatinine clearance.
  9. Have a history of congestive heart failure requiring pharmacologic treatment.
  10. Have a known hypersensitivity to metformin hydrochloride.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Group A (Crossover Group 1)

Subjects assigned to this arm will receive metformin first, followed by a washout period and then placebo.

Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.

Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.

実験的:Group B (Crossover Group 2)

Subjects assigned to this arm will receive placebo first, followed by a washout period and then metformin.

Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.

Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Feasibility: Medication Adherence
時間枠:Outcome 2 (Week 35)

Participant's adherence to taking study medication (Metformin or Placebo) as instructed based on dosing nomogram, for the whole study.

% Medication adherence = (Number of tablets actually consumed / Number of tablets expected to be consumed)*100

Number of tablets actually consumed is based on compliance counts conducted at the end of the study.

Outcome 2 (Week 35)
Safety: Frequency of Adverse Events (AE)
時間枠:Outcome 2 (Week 35)

The frequency of all AEs experienced during metformin and placebo treatment for all participants.

Outcome 2 (Week 35)

二次結果の測定

結果測定
メジャーの説明
時間枠
Cognitive Testing: Declarative Memory - Change in Children's Auditory Verbal Learning Test -2 (CAVLT-2)
時間枠:Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)

For Arm AB:

  1. Change in Immediate Recall test from Baseline 1 (Week 1) at Outcome 1 (Week 13, post 12-week intervention)
  2. Change in Immediate Recall test from Baseline 2 (Week 23, post 10-week washout) at Outcome 2 (Week 35, post 2nd 12-week intervention)
  3. Change in Immediate Recall test from Baseline 1 (Week 1) at Outcome 2 (Week 35, post 2nd 12-week intervention)

For Arm BA:

  1. Change in Immediate Recall test from Baseline 1 (Week 1) at Outcome 1 (Week 13)
  2. Change in Immediate Recall test from Baseline 2 (Week 23) at Outcome 2 (Week 35)
  3. Change in Immediate Recall test from Baseline 1 (Week 1) at Outcome 2 (Week 35)
Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)
Cognitive Testing: Working Memory - Change in List Sort Working Memory Subtest of the NIH Toolbox Cognition Battery
時間枠:Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), Outcome 2 (Week 35)

For Arm AB:

  1. Change in List Sort Working Memory Test from Baseline 1 (Week 1) at Outcome 1 (Week 13)
  2. Change in List Sort Working Memory Test from Baseline 2 (Week 23) at Outcome 2 (Week 35)
  3. Change in List Sort Working Memory Test from Baseline 1 (Week 1) at Outcome 2 (Week 35)

For Arm BA:

  1. Change in List Sort Working Memory Test from Baseline 1 (Week 1) at Outcome 1 (Week 13)
  2. Change in List Sort Working Memory Test from Baseline 2 (Week 23) at Outcome 2 (Week 35)
  3. Change in List Sort Working Memory Test from Baseline 1 (Week 1) at Outcome 2 (Week 35)
Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), Outcome 2 (Week 35)
Cognitive Testing: Processing Speed - Change in Mean Reaction Time across Cambridge Neuropsychological Test Automated Battery (CANTAB) subtests
時間枠:Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)

Change in Mean Reaction Time (MRT) across the following CANTAB subtests:

  1. Rapid Visual Information Processing (RVP)
  2. Reaction Time (RT)
  3. Match to Sample Visual Search (MTS)
  4. Delayed Matching in sample (DMS)

Each subtest provides an outcome measure of response latency, which will be averaged across all correct trials for each subtest to provide an overall measure of processing speed.

For Arm AB:

  1. Change in MRT from Baseline 1 (Week 1) at Outcome 1 (Week 13)
  2. Change in MRT from Baseline 2 (Week 23) at Outcome 2 (Week 35)
  3. Change in MRT from Baseline 1 (Week 1) at Outcome 2 (Week 35)

For Arm BA:

  1. Change in MRT from Baseline 1 (Week 1) at Outcome 1 (Week 13)
  2. Change in MRT from Baseline 2 (Week 23) at Outcome 2 (Week 35)
  3. Change in MRT from Baseline 1 (Week 1) at Outcome 2 (Week 35)
Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)

その他の成果指標

結果測定
メジャーの説明
時間枠
Neuroimaging: MRI Measures of White Matter Growth within the Corpus Callosum
時間枠:Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)

Change in Axonal Water Fraction (AWF)- Diffusion Kurtosis Imaging (DKI) metric sensitive to myelin

Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)
Neuroimaging: MRI Measures of Hippocampal Volume
時間枠:Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35

Change in Hippocampal Volume, as measured by Cerebral Blood Flow (CBF)

Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Donald Mabbott, PhD、The Hospital for Sick Children

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2014年6月13日

一次修了 (実際)

2017年12月15日

研究の完了 (実際)

2017年12月15日

試験登録日

最初に提出

2014年1月7日

QC基準を満たした最初の提出物

2014年1月15日

最初の投稿 (推定)

2014年1月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月24日

QC基準を満たした最後の更新が送信されました

2026年9月21日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する